Silo Pharma soars on positive data in arthritis drug study

Silo Pharma

30/12/2022 14:11

** Shares of Silo Pharma Inc  SILO.O  rise 56.4% to $5.4
before the bell
    ** SILO, which is focused on the treatment of neurological
disorders, reports positive interim data from study of potential
arthritis drug SPU-21
    ** Arthritis is a condition with swelling and tenderness of
one or more joints 
    ** SPU-21 in the dose optimization study was effective in
controlling arthritis progression - SILO
    ** The animal study evaluated the disease-suppressive
effects of an SPU-21 peptide-guided anti-arthritis drug versus
the drug alone
    ** YTD, SILO down 52%, as of last close 
 (Reporting by Pratik Jain in Bengaluru)
 ((Pratik.Jain@thomsonreuters.com;))